Menopause and cardiovascular disease: the evidence

References

• Eberhardt V MS. Health, United States, 2001. National Center for Health Statistics. 2001; 189–192
   Google Scholar
• Ries L AG. SEER Cancer Statistics Review, 1973–1998. National Cancer Institute. 2001
   Google Scholar
• Castelli W P. Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study. Can J Cardiol 1988; 4(Suppl A)5–10A
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee. European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw G J, Murphy M B, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–1630
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani A R. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001; 39: 125–132
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism 1995; 44(Suppl 3)15–17
   PubMedGoogle Scholar
• Lindheim S R, Buchanan T A, Duffy D M, et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1994; 1: 150–154
   PubMedGoogle Scholar
• Hu G. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003; 46: 608–617
   PubMed Web of Science ®Google Scholar
• Wilson P WF, Kannel W B. Epidemiology of hyperglycemia and atherosclerosis. Hyperglycemia, Diabetes and Vascular Disease, N Ruderman, J Williamson, M Brownlee. Oxford University Press, New York 1992; 21–29
   Google Scholar
• Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K, DECODE Study Group; European Diabetes Epidemiology Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004; 47: 2118–2128
   PubMed Web of Science ®Google Scholar
• Bakris G L, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646–661
   PubMed Web of Science ®Google Scholar
• Kannel W B, Cupples L A, D'Agostino R B, Stokes J, 3rd. Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham Study. Hypertension 1988; 11: 1145–1150
   Google Scholar
• Sever P S, Dahlof B, Poulter N R, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158
   PubMed Web of Science ®Google Scholar
• Wong N D, Pio J R, Franklin S S, L'Italien G J, Kamath T V, Williams G R. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 1421–1426
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Phillips L S, Langer R D. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558–566
   PubMed Web of Science ®Google Scholar
• Salpeter S R, Walsh J M, Greyber E, Ormiston T M, Salpeter E E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791–804
   PubMed Web of Science ®Google Scholar
• Prentice R L, Langer R, Stefanick M L, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162: 404–414
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Anderson G, Psaty B M, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000; 36: 780–789
   PubMed Web of Science ®Google Scholar
• Wilson P W, Garrison R J, Castelli W P. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985; 313: 1038–1043
   PubMed Web of Science ®Google Scholar
• Archer D F, Thorneycroft I H, Foegh M, et al. Long-term safety of drospirenone–estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–727
   PubMed Web of Science ®Google Scholar
• Preston R A, White W B, Pitt B, Bakris G, Norris P M, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797–804
   PubMed Web of Science ®Google Scholar
• White W B, Pitt B, Preston R A, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112: 1979–1984
   PubMed Web of Science ®Google Scholar
• White W B, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48: 246–253
   PubMed Web of Science ®Google Scholar